Literature DB >> 19015959

Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors.

Markus Gantert1, Felicitas Lewrick, Joanna E Adrian, Jochen Rössler, Thomas Steenpass, Rolf Schubert, Regine Peschka-Süss.   

Abstract

PURPOSE: The challenge in developing liposomes to be used in active drug targeting is to design a method that can be used for modifying liposomal membranes that is applicable for a number of different specific ligands. In this study, the post insertion technique was used with activated sterol-PEG(1300) anchors and was evaluated with regard to its effectiveness in active targeting in vitro. The key advantage of these anchors is that the insertion step into the liposomal membrane takes place at room temperature and is very fast.
MATERIALS AND METHODS: For in vitro experiments, neuroblastoma cell lines overexpressing GD2 antigen on their surface as a target structure were chosen. This allowed the use of anti-GD2 antibodies coupled to the liposomal surface for testing of specific binding. These modified liposomes were labelled with rhodamine-PE and their cellular association was analyzed by flow cytometry.
RESULTS: It was shown that the activated sterol-PEG(1300) anchors allow specific and significant interactions of the modified liposomes with GD2 positive cells.
CONCLUSION: Coupling using sterol-PEG(1300) anchors is both simple and rapid. It is reproducible and applicable for all ligands bearing amino groups. This method demonstrates the advantage of a ready-to-use system for the modification of pre-formed liposomes with different ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015959     DOI: 10.1007/s11095-008-9768-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Clearance properties of liposomes involving conjugated proteins for targeting.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-06-08       Impact factor: 15.470

2.  Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles.

Authors:  A R Nicholas; M J Scott; N I Kennedy; M N Jones
Journal:  Biochim Biophys Acta       Date:  2000-01-15

3.  In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.

Authors:  D L Iden; T M Allen
Journal:  Biochim Biophys Acta       Date:  2001-08-06

4.  GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide.

Authors:  G Pagnan; P G Montaldo; F Pastorino; L Raffaghello; M Kirchmeier; T M Allen; M Ponzoni
Journal:  Int J Cancer       Date:  1999-04-12       Impact factor: 7.396

5.  Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.

Authors:  Leonid S Metelitsa; Stephen D Gillies; Michael Super; Hiroyuki Shimada; C Patrick Reynolds; Robert C Seeger
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

6.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

Authors:  V P Torchilin; T S Levchenko; A N Lukyanov; B A Khaw; A L Klibanov; R Rammohan; G P Samokhin; K R Whiteman
Journal:  Biochim Biophys Acta       Date:  2001-04-02

7.  Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

Authors:  Fabio Pastorino; Chiara Brignole; Danilo Marimpietri; Gabriella Pagnan; Adriana Morando; Domenico Ribatti; Sean C Semple; Claudio Gambini; Theresa M Allen; Mirco Ponzoni
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

Review 8.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

9.  Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.

Authors:  M M Uttenreuther-Fischer; C S Huang; A L Yu
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

10.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures.

Authors:  C B Hansen; G Y Kao; E H Moase; S Zalipsky; T M Allen
Journal:  Biochim Biophys Acta       Date:  1995-11-01
View more
  7 in total

1.  Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

Authors:  Andrea Orthmann; Reiner Zeisig; Regine Süss; Dorothea Lorenz; Margit Lemm; Iduna Fichtner
Journal:  Pharm Res       Date:  2012-03-08       Impact factor: 4.200

Review 2.  Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.

Authors:  Anu Puri; Kristin Loomis; Brandon Smith; Jae-Ho Lee; Amichai Yavlovich; Eliahu Heldman; Robert Blumenthal
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2009       Impact factor: 4.889

3.  Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method.

Authors:  Joanna E Adrian; Alexander Wolf; Annette Steinbach; Jochen Rössler; Regine Süss
Journal:  Pharm Res       Date:  2011-05-19       Impact factor: 4.200

4.  Mixing solutions in inkjet formed vesicles.

Authors:  Thomas H Li; Jeanne C Stachowiak; Daniel A Fletcher
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

5.  Characterization of spherulites as a lipidic carrier for low and high molecular weight agents.

Authors:  Peng Zhang; Yixian Huang; Alexander M Makhov; Xiang Gao; Peijun Zhang; Song Li
Journal:  Pharm Res       Date:  2013-04-12       Impact factor: 4.200

6.  MRI-based molecular imaging of epicardium-derived stromal cells (EpiSC) by peptide-mediated active targeting.

Authors:  Tamara Straub; Julia Nave; Pascal Bouvain; Mohammad Akbarzadeh; Siva Sai Krishna Dasa; Julia Kistner; Zhaoping Ding; Aseel Marzoq; Stefanie Stepanow; Katrin Becker; Julia Hesse; Karl Köhrer; Ulrich Flögel; Mohammad R Ahmadian; Brent A French; Jürgen Schrader; Sebastian Temme
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

7.  Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.

Authors:  Judith Jakoby; Felix Beuschlein; Susanne Mentz; Constanze Hantel; Regine Süss
Journal:  Oncotarget       Date:  2015-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.